Exotoxins produced by certain strains of streptococci, particularly those of group A (STREPTOCOCCUS PYOGENES), that cause HEMOLYSIS.
Antibodies specific to STREPTOLYSINS which indicate STREPTOCOCCAL INFECTIONS.
Infection with group A streptococci that is characterized by tonsillitis and pharyngitis. An erythematous rash is commonly present.
A species of gram-positive, coccoid bacteria isolated from skin lesions, blood, inflammatory exudates, and the upper respiratory tract of humans. It is a group A hemolytic Streptococcus that can cause SCARLET FEVER and RHEUMATIC FEVER.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
A febrile disease occurring as a delayed sequela of infections with STREPTOCOCCUS PYOGENES. It is characterized by multiple focal inflammatory lesions of the connective tissue structures, such as the heart, blood vessels, and joints (POLYARTHRITIS) and brain, and by the presence of ASCHOFF BODIES in the myocardium and skin.

Maintenance of motility in mouse sperm permeabilized with streptolysin O. (1/614)

One approach to studying the mechanisms governing sperm motility is to permeabilize sperm and examine the regulation of motility by manipulating the intracellular milieu of the cell. The most common method of sperm permeabilization, detergent treatment, has the disadvantage that the membranes and many proteins are extracted from the cell. To avoid this problem, we have developed a method that uses streptolysin O to create stable pores within the plasma membrane while leaving internal membranes intact. Sperm were permeabilized, preincubated, and then treated with 0.6 U/ml of streptolysin O. Permeabilization was assessed by fluorescent dye technologies and endogenous protein phosphorylation using exogenously added [gamma-32P]ATP. Streptolysin O-induced permeabilization rendered the sperm immotile, and the effect was Ca2+-dependent. When the cells were treated simultaneously with a medium containing ATP, streptolysin O-treated sperm maintained flagellar movement. These results demonstrate that the streptolysin O permeabilization model system is a useful experimental method for studying the mechanisms that regulate sperm motility since it allows the flagellar apparatus to be exposed to various exogenously added molecules.  (+info)

Rapid and reliable identification of Streptococcus pneumoniae isolates by pneumolysin-mediated agglutination. (2/614)

A pneumolysin-based agglutination test which allows an easy, rapid, cost-effective, and accurate (100% specific and 95% sensitive) discrimination between pneumococci and other related human and animal pathogenic bacterial strains has been assayed.  (+info)

Molecular characterization of equine isolates of Streptococcus pneumoniae: natural disruption of genes encoding the virulence factors pneumolysin and autolysin. (3/614)

Although often considered a strict human pathogen, Streptococcus pneumoniae has been reported to infect and cause pneumonia in horses, although the pathology appears restricted compared to that of human infections. Here we report on the molecular characterization of a group of S. pneumoniae isolates obtained from horses in England and Ireland. Despite being obtained from geographically distinct locations, the isolates were found to represent a tight clonal group, virtually identical to each other but genetically distinguishable from more than 120 divergent isolates of human S. pneumoniae. A comprehensive analysis of known pneumococcal virulence determinants was undertaken in an attempt to understand the pathogenicity of equine pneumococci. Surprisingly, equine isolates appear to lack activities associated with both the hemolytic cytotoxin pneumolysin, often considered a major virulence factor of pneumococci, and the major autolysin gene lytA, also considered an important virulence factor. In support of phenotypic data, molecular studies demonstrated a deletion of parts of the coding sequences of both lytA and ply genes in equine pneumococci. The implications of these findings for the evolution and pathogenicity of equine S. pneumoniae are discussed.  (+info)

Role of Pneumolysin's complement-activating activity during pneumococcal bacteremia in cirrhotic rats. (4/614)

We investigated the role of pneumolysin's complement-activating activity during Streptococcus pneumoniae bacteremia in a hypocomplementemic, cirrhotic host. Isogenic mutant pneumococcal strains, in which pneumolysin was expressed from a plasmid, were used. These strains included H+C+, expressing wild-type pneumolysin with both cytolytic and complement-activating activity; PLY-, carrying the plasmid without the pneumolysin gene; and, H+C-, expressing pneumolysin with cytolytic activity only. In control rats, intravenous infection with 2.0 x 10(7) CFU of H+C+ per ml of blood resulted in a decrease in bacteremia of 3.5 log units by 18 h postinfection and 55% mortality. By contrast, cirrhotic rats infected similarly with the H+C+ strain demonstrated a 0.2-log-unit increase in bacteremia by 18 h postinfection and 100% mortality. Both control and cirrhotic rats cleared the PLY- strain more effectively from their bloodstreams by 18 h postinfection (6.2 and 5. 6 log unit decreases, respectively). Infection with the PLY- strain also resulted in low mortality (0 and 14%, respectively) for control and cirrhotic rats. When infected with the H+C- strain (without complement-activating activity), both groups cleared the organism from their bloodstreams nearly as well as they did the PLY- strain. Furthermore, the mortality rate for control and cirrhotic rats was identical after infection with the H+C- strain. These studies suggest that pneumolysin production contributes to decreased pneumococcal clearance from the bloodstream and higher mortality in both control and cirrhotic rats. However, pneumolysin's complement-activating activity may uniquely enhance pneumococcal virulence in the hypocomplementemic, cirrhotic host.  (+info)

Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. (5/614)

The human pathogen Streptococcus pneumoniae produces soluble pneumolysin monomers that bind host cell membranes to form ring-shaped, oligomeric pores. We have determined three-dimensional structures of a helical oligomer of pneumolysin and of a membrane-bound ring form by cryo-electron microscopy. Fitting the four domains from the crystal structure of the closely related perfringolysin reveals major domain rotations during pore assembly. Oligomerization results in the expulsion of domain 3 from its original position in the monomer. However, domain 3 reassociates with the other domains in the membrane pore form. The base of domain 4 contacts the bilayer, possibly along with an extension of domain 3. These results reveal a two-stage mechanism for pore formation by the cholesterol-binding toxins.  (+info)

A response regulator that represses transcription of several virulence operons in the group A streptococcus. (6/614)

A search for homologs of the Bacillus subtilis PhoP response regulator in the group A streptococcus (GAS) genome revealed three good candidates. Inactivation of one of these, recently identified as csrR (J. C. Levin and M. R. Wessels, Mol. Microbiol. 30:209-219, 1998), caused the strain to produce mucoid colonies and to increase transcription of hasA, the first gene in the operon for capsule synthesis. We report here that a nonpolar insertion in this gene also increased transcription of ska (encoding streptokinase), sagA (streptolysin S), and speMF (mitogenic factor) but did not affect transcription of slo (streptolysin O), mga (multiple gene regulator of GAS), emm (M protein), scpA (complement C5a peptidase), or speB or speC (pyrogenic exotoxins B and C). The amounts of streptokinase, streptolysin S, and capsule paralleled the levels of transcription of their genes in all cases. Because CsrR represses genes unrelated to those for capsule synthesis, and because CsrA-CsrB is a global regulatory system in Escherichia coli whose mechanism is unrelated to that of these genes in GAS, the locus has been renamed covR, for "control of virulence genes" in GAS. Transcription of the covR operon was also increased in the nonpolar insertion mutant, indicating that CovR represses its own synthesis as well. All phenotypes of the covR nonpolar insertion mutant were complemented by the covR gene on a plasmid. CovR acts on operons expressed both in exponential and in stationary phase, demonstrating that the CovR-CovS pathway is separate from growth phase-dependent regulation in GAS. Therefore, CovR is the first multiple-gene repressor of virulence factors described for this important human pathogen.  (+info)

Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. (7/614)

Invasive infection with Gram-positive and Gram-negative bacteria often results in septic shock and death. The basis for the earliest steps in innate immune response to Gram-positive bacterial infection is poorly understood. The LPS component of the Gram-negative bacterial cell wall appears to activate cells via CD14 and Toll-like receptor (TLR) 2 and TLR4. We hypothesized that Gram-positive bacteria might also be recognized by TLRs. Heterologous expression of human TLR2, but not TLR4, in fibroblasts conferred responsiveness to Staphylococcus aureus and Streptococcus pneumoniae as evidenced by inducible translocation of NF-kappaB. CD14 coexpression synergistically enhanced TLR2-mediated activation. To determine which components of Gram-positive cell walls activate Toll proteins, we tested a soluble preparation of peptidoglycan prepared from S. aureus. Soluble peptidoglycan substituted for whole organisms. These data suggest that the similarity of clinical response to invasive infection by Gram-positive and Gram-negative bacteria is due to bacterial recognition via similar TLRs.  (+info)

Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. (8/614)

Nitric oxide (NO) production by inducible NO synthase (iNOS) during inflammation is an essential element of antimicrobial immunity but can also contribute to host-induced tissue damage. Under conditions of bacterial sepsis, large amounts of NO are produced, causing hypotension, a critical pathological feature of septic shock. In sepsis caused by gram-positive organisms, the bacterial factors contributing to host NO production are poorly characterized. We show that a soluble toxin of Streptococcus pneumoniae, pneumolysin (Pln), is a key component initiating NO production from macrophages. In contrast to wild-type bacteria, a mutant of S. pneumoniae lacking Pln failed to elicit NO production from murine macrophages. Purified recombinant Pln induced NO production at low concentrations and independently of exogenous gamma interferon (IFN-gamma) priming of RAW 264.7 macrophages. However, IFN-gamma was essential for Pln-induced NO production, since primary macrophages from mice lacking the IFN-gamma receptor or interferon regulatory factor 1, a transcription factor essential for iNOS expression, failed to produce NO when stimulated with Pln. In addition, Pln acts as an agonist of tumor necrosis factor alpha and interleukin 6 production in macrophages. The properties of Pln, previously identified as a pore-forming hemolysin, also include a role as a general inflammatory agonist.  (+info)

Streptolysins are exotoxins produced by certain strains of Streptococcus bacteria, primarily Group A Streptococcus (GAS). These toxins are classified into two types: streptolysin O (SLO) and streptolysin S (SLS).

1. Streptolysin O (SLO): It is a protein exotoxin that exhibits oxygen-labile hemolytic activity, meaning it can lyse or destroy red blood cells in the presence of oxygen. SLO is capable of entering host cells and causing various cellular damages, including inhibition of phagocytosis, modulation of immune responses, and induction of apoptosis (programmed cell death).

2. Streptolysin S (SLS): It is a non-protein, oxygen-stable hemolysin that can also lyse red blood cells but does so independently of oxygen presence. SLS is more heat-resistant than SLO and has a stronger ability to penetrate host cell membranes.

Both streptolysins contribute to the virulence of Streptococcus pyogenes, which can cause various clinical infections such as pharyngitis (strep throat), impetigo, scarlet fever, and invasive diseases like necrotizing fasciitis and toxic shock syndrome.

The detection of streptolysin O antibodies (ASO titer) is often used as a diagnostic marker for past or recent GAS infections, particularly in cases of rheumatic fever, where elevated ASO titers indicate ongoing or previous streptococcal infection.

Antistreptolysin (ASO) is a type of antibody that the body produces in response to an infection caused by Streptococcus pyogenes, a species of bacteria commonly known as group A streptococcus. This bacterium produces a toxin called streptolysin O, which can damage tissues and cells in the body. The ASO antibodies are produced by the immune system to help neutralize the effects of this toxin and protect against further tissue damage.

ASO titers, or levels of these antibodies in the blood, can be measured through a laboratory test called an antistreptolysin O titer test. This test is often used to help diagnose recent streptococcal infections, such as strep throat, and to monitor the effectiveness of treatment. Elevated ASO titers may indicate a recent or ongoing infection with group A streptococcus, while normal or decreasing titers suggest that the infection has resolved.

It's important to note that a positive ASO test does not necessarily mean that a person is currently infected with group A streptococcus, as these antibodies can persist in the blood for several months after an infection has cleared. Therefore, the test should be interpreted in conjunction with other clinical findings and laboratory results.

Scarlet Fever is a bacterial illness that mainly affects children and is characterized by a bright red rash on the body, high fever, and a sore throat. It's caused by Group A Streptococcus bacteria (Strep throat) and is treatable with antibiotics. The distinctive red rash associated with Scarlet Fever is due to toxins produced by the bacteria, which can also cause other symptoms such as flushed face, strawberry tongue, and a pale ring around the mouth. If left untreated, Scarlet Fever can lead to serious complications like kidney damage or rheumatic fever.

Streptococcus pyogenes is a Gram-positive, beta-hemolytic streptococcus bacterium that causes various suppurative (pus-forming) and nonsuppurative infections in humans. It is also known as group A Streptococcus (GAS) due to its ability to produce the M protein, which confers type-specific antigenicity and allows for serological classification into more than 200 distinct Lancefield groups.

S. pyogenes is responsible for a wide range of clinical manifestations, including pharyngitis (strep throat), impetigo, cellulitis, erysipelas, scarlet fever, rheumatic fever, and acute poststreptococcal glomerulonephritis. In rare cases, it can lead to invasive diseases such as necrotizing fasciitis (flesh-eating disease) and streptococcal toxic shock syndrome (STSS).

The bacterium is typically transmitted through respiratory droplets or direct contact with infected skin lesions. Effective prevention strategies include good hygiene practices, such as frequent handwashing and avoiding sharing personal items, as well as prompt recognition and treatment of infections to prevent spread.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

Hemolysis is the destruction or breakdown of red blood cells, resulting in the release of hemoglobin into the surrounding fluid (plasma). This process can occur due to various reasons such as chemical agents, infections, autoimmune disorders, mechanical trauma, or genetic abnormalities. Hemolysis may lead to anemia and jaundice, among other complications. It is essential to monitor hemolysis levels in patients undergoing medical treatments that might cause this condition.

Rheumatic fever is a systemic inflammatory disease that may occur following an untreated Group A streptococcal infection, such as strep throat. It primarily affects children between the ages of 5 and 15, but it can occur at any age. The condition is characterized by inflammation in various parts of the body, including the heart (carditis), joints (arthritis), skin (erythema marginatum, subcutaneous nodules), and brain (Sydenham's chorea).

The onset of rheumatic fever usually occurs 2-4 weeks after a streptococcal infection. The exact cause of the immune system's overreaction leading to rheumatic fever is not fully understood, but it involves molecular mimicry between streptococcal antigens and host tissues.

The Jones Criteria are used to diagnose rheumatic fever, which include:

1. Evidence of a preceding streptococcal infection (e.g., positive throat culture or rapid strep test, elevated or rising anti-streptolysin O titer)
2. Carditis (heart inflammation), including new murmurs or changes in existing murmurs, electrocardiogram abnormalities, or evidence of heart failure
3. Polyarthritis (inflammation of multiple joints) – typically large joints like the knees and ankles, migratory, and may be associated with warmth, swelling, and pain
4. Erythema marginatum (a skin rash characterized by pink or red, irregularly shaped macules or rings that blanch in the center and spread outward)
5. Subcutaneous nodules (firm, round, mobile lumps under the skin, usually over bony prominences)
6. Sydenham's chorea (involuntary, rapid, irregular movements, often affecting the face, hands, and feet)

Treatment of rheumatic fever typically involves antibiotics to eliminate any residual streptococcal infection, anti-inflammatory medications like corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to manage symptoms and prevent long-term heart complications, and secondary prophylaxis with regular antibiotic administration to prevent recurrent streptococcal infections.

Categories: Streptolysins Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted 2 ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins / genetics Actions. * Search in PubMed * Search in MeSH * Add to Search ...
... including streptolysins, deoxyribonucleases, and pyrogenic exotoxins, which cause tissue destruction and induce an excessive ...
The "O" in the name stands for oxygen-labile; the other related toxin being oxygen-stable streptolysin-S. The main function of ...
Experimental studies on streptococcal infection and rheumatic fever; studies on streptolysins; preparation, improved methods of ... Experimental studies on streptococcal infection and rheumatic fever; studies on streptolysins; preparation, improved methods of ... Experimental studies on streptococcal infection and rheumatic fever; studies on streptolysins; preparation, improved methods of ... Experimental studies on streptococcal infection and rheumatic fever; studies on streptolysins; preparation, improved methods of ...
Streptolysins - Preferred Concept UI. M0020589. Scope note. Exotoxins produced by certain strains of streptococci, particularly ...
Streptolysins Preferred Term Term UI T039067. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1966). ... Streptolysins. Tree Number(s). D12.776.543.695.937. D23.946.123.868. D23.946.350.750. Unique ID. D013301. RDF Unique Identifier ... Streptolysins Preferred Concept UI. M0020589. Registry Number. 0. Scope Note. Exotoxins produced by certain strains of ... use STREPTOLYSINS to search STREPTOLYSIN 1966-77. History Note. 78; was STREPTOLYSIN 1963-77. Date Established. 1978/01/01. ...
Streptolysins Preferred Term Term UI T039067. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1966). ... Streptolysins. Tree Number(s). D12.776.543.695.937. D23.946.123.868. D23.946.350.750. Unique ID. D013301. RDF Unique Identifier ... Streptolysins Preferred Concept UI. M0020589. Registry Number. 0. Scope Note. Exotoxins produced by certain strains of ... use STREPTOLYSINS to search STREPTOLYSIN 1966-77. History Note. 78; was STREPTOLYSIN 1963-77. Date Established. 1978/01/01. ...
Many streptococci elaborate virulence factors, including streptolysins, DNAases, and hyaluronidase, which contribute to tissue ...
Many streptococci elaborate virulence factors, including streptolysins, DNAases, and hyaluronidase, which contribute to tissue ...
... pneumococcus streptolysins,streptolysin streptomycins,aminoglycoside streptomycin,aminoglycoside stress test,exercise test ...
... streptolysins S and O. Of these 2 toxins, streptolysin O induces persistently high antibody titers that provide a useful marker ...
Streptolysins. 33. Antigens that provoke a very intense immune response due to the release of cytokines from host cells (T ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Streptolysins D12.776.543.695.937. Stroke Volume G9.330.553.400.280.882 G9.330.553.660.124.882. Sturge-Weber Syndrome C4.700. ...
Group A N0000170354 Streptogramin Group B N0000011418 Streptogramins N0000005882 Streptokinase N0000171403 Streptolysins ...

No FAQ available that match "streptolysins"

No images available that match "streptolysins"